Sales of ‘Viread’ started to soar up while sales of 'Baraclude' declined for the first time

Published: 2014-07-28 09:21:16

Updated: 2014-07-28 09:21:16

‘Viread’ started to soar up. Sales of 'Baraclude' declined for the first time.

Hepatitis B treatment markey where about five years of unparalleled dominance of one item had been accomplished, is changing.

On July 25, according to the analysis of 'Outpatient prescription status in the first half of 2014 (UBIST)' by Dailypharm, BMS's Baraclude (entecavir) recorded sales of 75.6 billion won and ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.